IRWD News and Press, Ironwood Pharmaceuticals Inc. From 02/28/22

PBE is neither suitable for income seekers, nor for long term investors. Despite being a Genomic revolution fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better biotechnology ETFs of similar nature are available in the market. For f...

Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2021 Earnings Conference Call February 17, 2022 08:30 A.M. ET Company Participants Matt Roache - Director of IR Thomas McCourt - CEO Michael Shetzline - CMO and Head of R&D Sravan K. Emany - CFO Conference Call Participants Boris Peaker - Cowen &am...

The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Ironwood Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation

Ironwood Pharmaceuticals press release (NASDAQ:IRWD): Q4 Non-GAAP EPS of $0.27 misses by $0.07. Revenue of $117.13M (+0.4% Y/Y) beats by $6.96M. Guidance:  FY22 The company expects the revenue to be between $420M -$430M (consensus of $426.90M). Adjusted EBITDA expected to be >$25...

– 2021 total revenue of $414 million, driven primarily by $400 million in U.S. LINZESS collaboration revenue – – 2021 GAAP net income of $528 million, includes a $338 million non-recurring income tax benefit related to the release of the valuation al...

Ironwood Pharmaceuticals (NASDAQ:IRWD) is scheduled to announce Q4 earnings results on Thursday, February 17th, before market open. The consensus EPS Estimate is $0.34 (-5.6% Y/Y) and the consensus Revenue Estimate is $110.17M (-5.6% Y/Y). Over the last 2 years, IRWD has beaten EPS estimates ...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 17, 2022. Individuals interested in participating in the call should dial (888...

– LINZESS Expected to Achieve Blockbuster Status with U.S. Net Sales in Excess of $1 Billion in 2021 – – Initiates Board Authorized Share Repurchase Program in Q4 2021 – ­– Expects Continued Double-Digit LINZESS® P...

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that Tom McCourt, CEO, will present at the 40 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 7:30 a.m. ET. The event is being held virtually and a l...

In his book “Super Stocks” published nearly 40 years ago, Ken Fisher described an investing philosophy about high growth companies, trading at a discount. The philosophy combines elements of high growth and value, including both quantitative and qualitative factors. ...